A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity (REDEFINE)
Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) in Participants With Hypertension and Obesity
This study is testing whether CagriSema is safe and works well in adults with high blood pressure and excess body weight. Participants will receive CagriSema, semaglutide, cagrilintide, or placebo, and treatment will be assigned by chance. CagriSema and cagrilintide are investigational medicines, while semaglutide is already available by prescription.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Estimado)
Inscripción
Fase
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
Estudio Contacto
- Nombre: Novo Nordisk
- Número de teléfono: (+1) 866-867-7178
- Correo electrónico: clinicaltrials@novonordisk.com
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 13405
- KARDIA - Dr. Hashemi
-
Duisburg, Alemania, 47269
- MVZ Hausärzte Großenbaum GmbH Duisburg
-
Elsterwerda, Alemania, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Frankfurt, Alemania, 60590
- Uniklinik FFM - Nephrologie
-
Hamburg, Alemania, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, Alemania, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, Alemania, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Buenos Aires, Argentina, C1425AGC
- Centro Medico Dra. Laura Maffei e Investigacion Clínica Apli
-
CABA, Argentina, C1060ABA
- CEDIC Centro de Investigación Clínica
-
CABA, Argentina, C1120AAC
- Centro Médico Viamonte SRL
-
Rosario, Argentina, S2000PBJ
- CAICI
-
Santiago del Estero, Argentina, G4200
- Sanatorio Norte
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, C1128 AAF
- Mautalen Salud e investigación
-
CABA, Buenos Aires, Argentina, C1440CFD
- CEMEDIC
-
Capital Federal, Buenos Aires, Argentina, C1056ABI
- Centro de Investigaciones Metabólicas
-
-
La Pampa Province
-
Santa Rosa, La Pampa Province, Argentina, 6300
- Fundación CESIM
-
-
Mendoza Province
-
Godoy Cruz, Mendoza, Mendoza Province, Argentina, 5501
- Hospital Español de Mendoza
-
-
-
-
New South Wales
-
Castle Hill, New South Wales, Australia, 2154
- Castle Hill Medical Centre
-
Darlinghurst, New South Wales, Australia, 2010
- Momentum Clinical Research Darlinghurst
-
Maroubra, New South Wales, Australia, 2035
- Australian Clinical Research Network
-
Sydney, New South Wales, Australia, 2148
- Roger Chih Yu Chen
-
-
Queensland
-
Douglas, Queensland, Australia, 4814
- Townsville University Hospital
-
-
Victoria
-
Torquay, Victoria, Australia, 3228
- Clinical Trials Institute
-
-
Western Australia
-
Bunbury, Western Australia, Australia, 6230
- Brecken Health Clinical Trials
-
Perth, Western Australia, Australia, 6000
- Dobney Hypertension Centre
-
-
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brasil, 30455-610
- Centro Universitário de Belo Horizonte (UNIBH)
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80230-130
- PUCPR - Pontificia Universidade Catolica do Parana
-
-
São Paulo
-
Bragança Paulista, São Paulo, Brasil, 12916-542
- Associação Lar São Francisco de Assis na Providência de Deus - Bragança Paulista
-
Campinas, São Paulo, Brasil, 13092-133
- i9 Pesquisas Clínicas
-
Campinas, São Paulo, Brasil, 13060-803
- PUCCAMP - Hospital e Maternidade Celso Pierro
-
Campinas, São Paulo, Brasil, 13083-887
- Centro de Pesquisa Clínica da Faculdade de Ciências Médicas - Unicamp
-
São Paulo, São Paulo, Brasil, 05403-000
- Instituto do Coração - HCFMUSP
-
São Paulo, São Paulo, Brasil, 04038-032
- IBTED Tecnologia e Educação em Diabetes - EPP
-
São Paulo, São Paulo, Brasil, 01228-000
- CPQuali Pesquisa Clínica Ltda
-
-
-
-
-
Burgas, Bulgaria, 8000
- Medical center Medconsult Burgas OOD
-
Panagyurishte, Bulgaria, 4500
- MHAT - Uni Hospital OOD, Clinic of Cardiology
-
Pernik, Bulgaria, 2308
- MHAT Rahila Angelova AD, Research Center
-
Plovdiv, Bulgaria, 4002
- Dr. Ilcho Ilchev - AIPSMC - Cardiology EOOD
-
Shumen, Bulgaria, 9700
- MHAT Shumen AD
-
Sliven, Bulgaria, 8800
- GPSMC - Inacor OOD
-
Sofia, Bulgaria, 1202
- DCC Ascendent OOD
-
Sofia, Bulgaria, 1231
- MC Dr. Atanasov EOOD
-
Sofia, Bulgaria, 1510
- MC Hera EOOD - Sofia
-
Sofia, Bulgaria, 1431
- UMHAT Aleksandrovska EAD, Clinic of Cardiology
-
Sofia, Bulgaria, 1750
- MHAT Sveta Anna Sofia AD, Clinic of Cardiology
-
Sofia, Bulgaria, 1527
- UMHAT Tsaritsa Yoanna - ISUL EAD, Cardiology
-
Sofia, Bulgaria, 1612
- Nevrovita - Medical Center OOD
-
Varna, Bulgaria, 9010
- UMHAT Sveta Marina EAD, Clinic of Internal Diseases
-
Varna, Bulgaria, 9009
- SHATC - Cardiolife OOD - Varna
-
-
-
-
-
Alken, Bélgica, 3570
- Anima Research Center
-
Bonheiden, Bélgica, 2820
- Imelda
-
Genk, Bélgica, 3600
- Ziekenhuis Oost-Limburg
-
Ghent, Bélgica, 9000
- Universitair Ziekenhuis Gent
-
Leuven, Bélgica, 3000
- Uz Leuven
-
Mons, Bélgica, 7000
- CHU Helora - Hôpital de Mons - Site Constantinople
-
-
-
-
-
Québec, Canadá, G1V 4T3
- Diex Recherche Quebec
-
Québec, Canadá, G1V 4G5
- IUCPQ - Universite Laval
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 2T1
- Spectrum Health Clinic
-
Victoria, British Columbia, Canadá, V8V 4A1
- Dr. M.B. Jones Inc
-
-
New Brunswick
-
Moncton, New Brunswick, Canadá, E1G 1A7
- G.A. Research Associates Ltd.
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3H 1V7
- Nova Scotia Health Authority
-
-
Ontario
-
Hamilton, Ontario, Canadá, L8L 5G4
- Premier Clinical Trial Research Network (PCTRN)
-
Hamilton, Ontario, Canadá, L8L 5G4
- Hamilton Medical Research Group
-
London, Ontario, Canadá, N5W 6A2
- Milestone Research
-
-
Quebec
-
Trois-Rivières, Quebec, Canadá, G9A 4P3
- Diex Recherche Trois-Rivieres
-
-
-
-
-
Busan, Corea del Sur, 49201
- Dong-A University Hospital_Family Medicine
-
Daegu, Corea del Sur, 41944
- Kyungpook National University Hospital_Family Medicine
-
Daegu, Corea del Sur, 42601
- Keimyung University Dongsan Hospital_Endocrinology
-
Daejeon, Corea del Sur, 35365
- Konyang University Hospital_Family Medicine
-
Seoul, Corea del Sur, 03722
- Severance Hospital, Yonsei University Health System_Family Medicine
-
Seoul, Corea del Sur, 04763
- Hanyang University Seoul Hospital_Family Medicine
-
-
Gyeonggi-do
-
Anyang-si, Gyeonggi-do, Corea del Sur, 14068
- Hallym University Sacred Heart Hospital_Family Medicine
-
Bucheon-si, Gyeonggi-do, Corea del Sur, 14647
- The Catholic University of Korea, Bucheon ST. Mary's Hospital_Endocrinology
-
Seongnam-si, Gyeonggi-do, Corea del Sur, 13620
- Seoul National University Bundang Hospital_Family Medicine
-
-
Gyeongsangnam-do
-
Yangsan, Gyeongsangnam-do, Corea del Sur, 50612
- Pusan National University Yangsan Hospital_Family Medicine
-
-
-
-
-
Herning, Dinamarca, 7400
- Regionshospitalet Gødstrup - Universitetsklinikken for Nyresygdomme og Blodtryksforhøjelse
-
Holbæk, Dinamarca, 4300
- Holbæk Sygehus - Forskningsenheden, Medicinsk Afdeling, afs. 44-4
-
Hvidovre, Dinamarca, 2650
- Hvidovre Hospital Endokrinologisk forsknings afsnit 159
-
Viborg, Dinamarca, 8800
- Viborg Sygehus
-
-
Region Syddanmark
-
Esbjerg, Region Syddanmark, Dinamarca, 6700
- Sydvestjysk Sygehus Esbjerg - Medicinsk Endokrinologisk Ambulatorium, Forskningsenheden
-
-
-
-
-
Badajoz, España, 06080
- Hospital Universitario de Badajoz
-
Barcelona, España, 08022
- Centro Médico Quirón-Teknon
-
Barcelona, España, 08036
- Clinic Barcelona_Endocrinología
-
León, España, 24008
- H. de León_Endocrinología
-
Madrid, España, 28016
- Hospital Universitario Sanitas Virgen del Mar
-
Madrid, España, 28009
- H.G.Marañón_Endocrino-Obesidad
-
Santander, España, 39008
- H. Univ. Marqués de Valdecilla_Endocrinología
-
Santiago de Compostela, España, 15702
- Clínica Gaias Santiago
-
-
-
-
California
-
Concord, California, Estados Unidos, 94520
- John Muir Physicians Network
-
Costa Mesa, California, Estados Unidos, 92627
- Aurora FDRC Inc.
-
Fullerton, California, Estados Unidos, 92835
- Providence Medical Foundation
-
Montclair, California, Estados Unidos, 91763
- Catalina Research Institute, LLC
-
Palm Springs, California, Estados Unidos, 92262
- Desert Oasis Hlthcr Med Group
-
San Dimas, California, Estados Unidos, 91773
- N America Res Inst - San Dimas
-
-
Connecticut
-
Waterbury, Connecticut, Estados Unidos, 06708
- Chase Medical Research LLC
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33765
- Clinical Res Of W Florida Inc
-
Ocala, Florida, Estados Unidos, 34470
- Renstar Medical Research
-
Orlando, Florida, Estados Unidos, 32825
- Florida Institute for Clinical research
-
-
Georgia
-
Albany, Georgia, Estados Unidos, 31707
- Javara Inc. / Privia Medical Group Georgia LLC
-
Conyers, Georgia, Estados Unidos, 30094
- Hope Clin Res & Wellness
-
Roswell, Georgia, Estados Unidos, 30076
- Endocrine Research Solutions, Inc
-
Savannah, Georgia, Estados Unidos, 31406
- Javara Inc. / Privia Medical Group Georgia LLC
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60640
- Great Lakes Clinical Trials
-
Morton, Illinois, Estados Unidos, 61550
- Koch Research
-
Skokie, Illinois, Estados Unidos, 60077
- Evanston Premier Hlthcr Res
-
Skokie, Illinois, Estados Unidos, 60077
- Endeavor Health
-
Springfield, Illinois, Estados Unidos, 62702
- SIU Medicine
-
-
Indiana
-
Indianapolis, Indiana, Estados Unidos, 46260
- Midwest Inst For Clin Res
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50266
- Iowa Diabetes Research
-
-
Kentucky
-
Bowling Green, Kentucky, Estados Unidos, 42101
- Graves Gibert Clinic
-
Louisville, Kentucky, Estados Unidos, 40213
- Monroe Biomedical Research, LLC
-
-
Michigan
-
Buckley, Michigan, Estados Unidos, 49620
- Northern Pines Hlth Ctr, PC
-
Flint, Michigan, Estados Unidos, 48504
- Aa Mrc Llc
-
-
Missouri
-
City of Saint Peters, Missouri, Estados Unidos, 63303
- StudyMetrix Research LLC
-
St Louis, Missouri, Estados Unidos, 63128
- Amicis Centers of Clinical Research
-
-
New Hampshire
-
Portsmouth, New Hampshire, Estados Unidos, 03801
- Seacoast Kidney & Htn Specialists
-
-
New York
-
West Seneca, New York, Estados Unidos, 14224
- Southgate Medical Group, LLP
-
Westfield, New York, Estados Unidos, 14787
- Great Lakes Medical Research
-
-
North Carolina
-
Raleigh, North Carolina, Estados Unidos, 27609
- Medication Management, LLC
-
Raleigh, North Carolina, Estados Unidos, 27609
- Accellacare_NC
-
Statesville, North Carolina, Estados Unidos, 28625
- Piedmont Healthcare, Inc.
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- Diab & Endo Assoc of Stark Co
-
Wadsworth, Ohio, Estados Unidos, 44281-9236
- Family Practice Center of Wadsworth Inc.
-
-
Oklahoma
-
Norman, Oklahoma, Estados Unidos, 73072
- Lynn Institute of Norman
-
-
Rhode Island
-
Cumberland, Rhode Island, Estados Unidos, 02864
- Clinical Res Collaborative
-
-
South Carolina
-
North Charleston, South Carolina, Estados Unidos, 29405
- Coastal Carolina Res Ctr
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Spartanburg Medical Research
-
-
Tennessee
-
Bristol, Tennessee, Estados Unidos, 37620
- Holston Medical Group Pc
-
Kingsport, Tennessee, Estados Unidos, 37660
- Holston Medical Group
-
Nashville, Tennessee, Estados Unidos, 37203
- Clinical Research Associates
-
-
Texas
-
Amarillo, Texas, Estados Unidos, 79124
- Amarillo Med Spec LLP
-
Austin, Texas, Estados Unidos, 78731
- Texas Diabetes & Endocrinology
-
Austin, Texas, Estados Unidos, 78749
- Texas Diabetes & Endocrinology, P.A._Austin
-
Bellaire, Texas, Estados Unidos, 77401
- Juno Research, LLC
-
Dallas, Texas, Estados Unidos, 75231
- North Texas Endocrine Center
-
Dallas, Texas, Estados Unidos, 75226
- Baylor Jack and Jane Hamilton
-
Dallas, Texas, Estados Unidos, 75230
- Velocity Clin Res, Dallas
-
Houston, Texas, Estados Unidos, 77079
- The Endocrine Center
-
Houston, Texas, Estados Unidos, 77036
- Discovery MM Services Inc
-
Lampasas, Texas, Estados Unidos, 76550
- Radiance Clinical Research
-
Longview, Texas, Estados Unidos, 75605
- DCOL Ctr for Clin Res
-
San Antonio, Texas, Estados Unidos, 78212
- Clinical Advancement Center
-
San Antonio, Texas, Estados Unidos, 78233
- Northeast Clinical Research of San Antonio
-
Shavano Park, Texas, Estados Unidos, 78231
- Consano Clinical Research, LLC
-
-
Washington
-
Renton, Washington, Estados Unidos, 98057
- Rainier Clin Res Ctr Inc
-
-
-
-
-
Budapest, Hungría, H-1141
- Cardiogeneral Kft.
-
Budapest, Hungría, 1046
- Újpesti Egészségközpont
-
Budapest, Hungría, H-1021
- Budapesti Szent Ferenc Kórház
-
Békéscsaba, Hungría, 5600
- Trial Pharma Kft.
-
Békéscsaba, Hungría, 5600
- Békés Vármegyei Központi Kórház
-
Szeged, Hungría, 6724
- KomplexLabor Diagnosztika Kft.
-
-
Bács-Kiskun county
-
Kalocsa, Bács-Kiskun county, Hungría, 6300
- Stúdium Egészségház Kft.
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, Hungría, 4032
- Debreceni Egyetem
-
-
-
-
Apulia
-
Bari, Apulia, Italia, 70124
- AUO Consorziale Policlinico Bari - UOC Medicina Interna Universitaria (Cesare Frugoni)
-
-
Calabria
-
Catanzaro, Calabria, Italia, 88100
- AOU Renato Dulbecco - Unità Operativa Complessa Medicina Interna
-
-
Emilia-Romagna
-
Ferrara, Emilia-Romagna, Italia, 44124
- Arcispedale Sant'Anna (Cona) - Medicina Interna Universitaria
-
-
Lazio
-
Rome, Lazio, Italia, 00189
- Azienda Ospedaliero - Universitaria Sant'Andrea - UOC Cardiologia
-
-
Lombardy
-
Brescia, Lombardy, Italia, 25123
- Spedali Civili Brescia - U.O. Medicina Generale 2
-
Milan, Lombardy, Italia, 20162
- Grande Ospedale Metropolitano Niguarda - Dipartimento di Cardiologia Clinica
-
-
Molise
-
Pozzilli (IS), Molise, Italia, 86077
- NeuroMed S.p.A. - Dipartimento di Angio-Cardio-Neurologia
-
-
RM
-
Rome, RM, Italia, 00168
- Fondazione Policlinico Universitario Agostino Gemelli IRCS
-
-
Sicily
-
Palermo, Sicily, Italia, 90127
- Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
-
-
The Marches
-
Ancorna, The Marches, Italia, 60127
- INRCA Ancona - UOC Clinica Medica e Geriatrica
-
-
Tuscany
-
Siena, Tuscany, Italia, 53100
- Azienda Ospedaliero Universitaria Senese - Endocrinologia
-
-
Veneto
-
Padova, Veneto, Italia, 35128
- Azienda Ospedaliera di Padova - UOSD Chirurgia Bariatrica
-
-
-
-
-
Arakawa-ku, Tokyo, Japón, 116-0012
- Kumanomae Nishimura Naika Clinic_Internal Medicine
-
Okayama, Japón, 700-8558
- Okayama University Hospital_Neph. and Diabetes, Metabolism
-
Sendai-shi, Miyagi, Japón, 983-0039
- Shinden Higashi Clinic_Internal medicine
-
Tokyo, Japón, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, Japón, 104-0031
- Fukuwa Clinic_Internal Medicine
-
Tokyo, Japón, 160-0004
- Clinical Research Hospital Tokyo_Internal medicine
-
-
Kanagawa
-
Yamato-shi, Kanagawa, Japón, 242-0004
- Tsuruma Kaneshiro Diabetes Clinic_Internal medicine
-
-
-
-
-
Deventer, Países Bajos, 7416 SE
- Deventer Ziekenhuis - Interne geneeskunde
-
Dordrecht, Países Bajos, 3318 AT
- Albert Schweitzer Zkh, Dordwijk - Nefrologie
-
Eindhoven, Países Bajos, 5623 EJ
- Catharina Zkh Eindhoven - Interne geneeskunde
-
Haarlem, Países Bajos, 2035 RC
- Spaarne Gasthuis Haarlem - Interne
-
Heerlen, Países Bajos, 6419 PC
- Zuyderland ziekenhuis - Interne
-
Hoogeveen, Países Bajos, 7909 AA
- Bethesda Diabetes Research Center
-
Nijmegen, Países Bajos, 6525 GA
- RadboudUMC - Vasculaire geneeskunde
-
Utrecht, Países Bajos, 3584 CX
- UMC Utrecht - Vasculaire geneeskunde
-
-
-
-
-
Elblag, Polonia, 82-300
- Centrum Kliniczno-Badawcze J. Brzezicki, B. Górnikiewicz-Brzezicka Lekarze Spółka Partnerska
-
Gdansk, Polonia, 80-214
- Uniwersyteckie Centrum Kliniczne
-
Gdansk, Polonia, 80-462
- Copernicus Podmiot Leczniczy Sp. z o.o.
-
Krakow, Polonia, 30-721
- Linden sp. z o.o. sp. k.
-
Krakow, Polonia, 31-322
- Gyncentrum Sp. z o. o.
-
Lodz, Polonia, 93-513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika
-
Rzeszów, Polonia, 35-205
- EMED Centrum Usług Medycznych Ewa Smialek
-
Siedlce, Polonia, 08-110
- Lukmed 2 Sp. z o.o.
-
Starachowice, Polonia, 27-200
- Star Badania Kliniczne Sp. z o.o
-
Warsaw, Polonia, 04-628
- Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
-
Świnoujście, Polonia, 72-600
- Balticmed Świnoujście Sp. z o. o.
-
-
Masovian Voivodeship
-
Grodzisk Mazowiecki, Masovian Voivodeship, Polonia, 05-825
- Samodzielny Publiczny Specjalistyczny Szpital Zachodni Im.Sw.Jana Pawla II
-
Ostrów Mazowiecka, Masovian Voivodeship, Polonia, 07-300
- Kresmed Sp. z o. o.
-
Warsaw, Masovian Voivodeship, Polonia, 04-635
- Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
-
-
Pomeranian Voivodeship
-
Gdynia, Pomeranian Voivodeship, Polonia, 81-157
- Ind. Spec. Prak. Lek. w dziedz. Kardiologii lek. med. K. Cymerman
-
-
-
-
-
Ponce, Puerto Rico, 00716
- Ponce Med School Found Inc
-
-
-
-
-
Bristol, Reino Unido, BS37 4AX
- West Walk Surgery
-
Cambridge, Reino Unido, CB2 0QQ
- Addenbrooke's Hospital_Cambridge
-
Chippenham, Reino Unido, SN14 6GT
- Hathaway Medical Centre
-
Harrow, Reino Unido, HA3 7LT
- Belmont Health Centre
-
Hounslow, Reino Unido, TW4 7NJ
- HMC Health - Heston - The Meadows Centre for Health
-
London, Reino Unido, EC1M 6BQ
- William Harvey Research Institute
-
London, Reino Unido, SW1P 2PF
- Healthcare Central London - South Westminster Centre for Health
-
-
Cambridgeshire
-
Wisbech, Cambridgeshire, Reino Unido, PE13 3UZ
- Trinity Surgery
-
-
Cornwall
-
Newquay, Cornwall, Reino Unido, TR7 1RU
- Newquay Health Centre
-
-
Hertfordshire
-
Bushey, Hertfordshire, Reino Unido, WD23 2NN
- Attenborough Surgery
-
-
-
-
Gauteng
-
Johannesburg, Gauteng, Sudáfrica, 2013
- Wits Bara Clinical Trial Site
-
Johannesburg, Gauteng, Sudáfrica, 1818
- Soweto Clinical Trial Centre
-
Midrand, Gauteng, Sudáfrica, 1685
- Dr A Jacovides and Partners Inc
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Sudáfrica, 4091
- Dr Vawda's site
-
eMkhomazi, KwaZulu-Natal, Sudáfrica, 4170
- Dr T Padayachee
-
-
Lenasia
-
Gauteng, Lenasia, Sudáfrica, 1827
- Dr Moosa's Rooms
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female (sex at birth).
- Age 18 years or above at the time of signing the informed consent.
- Resting in-office SBP of 140-160 mmHg (both inclusive) at screening (V1-Optional/V1) and the Run-in visit. Systolic blood pressure will be calculated as the mean of the second and third consecutive readings of triplicated blood pressure readings collected at 2-minute intervals with the blood pressure monitor provided by the Sponsor.
- Body mass index greater than or equal to (>=) 30.0 kilograms per metre square (kg/m^2) at screening.
- Not receiving Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) or antihypertensive medication or on stable (i.e., same drug(s), dose and dosing frequency) SGLT2i or antihypertensive treatment >= 30 days prior to screening.
For participants with Type 2 Diabetes (T2D)
The following inclusion criteria apply at screening in addition to the inclusion criteria listed above:
- Diagnosed with T2D >= 90 days before screening.
- Glycated Haemoglobin (HbA1c) 6.5-10.0% (48-86 millimoles per mole (mmol/mol)) (both inclusive) as measured by the central laboratory at screening.
- Treatment with either lifestyle intervention only, or treatment with 1-3 marketed oral antidiabetic drugs (metformin, α-glucosidase inhibitors, glinides, SGLT2i or thiazolidinediones, as a single agent or in combination) according to local label.
- Treatment with antidiabetic medication should be stable (i.e., same drug(s), dose and dosing frequency) for at least 90 days before screening.
Exclusion Criteria:
- Known orthostatic hypotension or orthostatic hypotension at screening (V1-Optional/V1).
- Known secondary hypertension due to renovascular hypertension (renal artery stenosis), primary aldosteronism, Cushing's syndrome, pheochromocytoma, acromegaly, coarctation of the aorta, or any other identifiable cause of secondary hypertension.
- Currently under medical investigation for any cause of secondary hypertension.
- Hospitalisation within the last 90 days before screening for hypertension or hypertensive crisis.
- Atrial fibrillation at the Run-in visit or history of frequent intermittent or chronic atrial fibrillation.
- Moderate-to-severe anaemia with Hgb lesser than (<) 10.9 grams per decilitre (g/dL) as measured by the central lab at screening.
- A change in body weight greater than (>) 5% within 90 days before screening irrespective of medical records.
- Treatment with any medication prescribed for the indication of obesity or weight management within 90 days before screening.
- Use of any Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA), including medication with GLP-1 RA activity, or amylin agonists, within 90 days before screening.
For participants without T2D
- HbA1c greater than or equal to >= 6.5 % (48 mmol/mol) as measured by the central laboratory at screening.
- History of type 1 or type 2 diabetes mellitus.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Cuadruplicar
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: CagriSema
Participants will receive CagriSema subcutaneously once weekly. |
CagriSema will be administered subcutaneously. |
|
Comparador activo: Semaglutide
Participants will receive semaglutide subcutaneously once weekly. |
Semaglutide will be administered subcutaneously. |
|
Comparador activo: Cagrilintide
Participants will receive cagrilintide subcutaneously once weekly. |
Cagrilintide will be administered subcutaneously. |
|
Comparador de placebos: Placebo
Participants will receive placebo subcutaneously once weekly. |
Placebo will be administered subcutaneously. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
CagriSema versus Placebo : Change in in-office systolic blood pressure (SBP)
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in millimeters of mercury (mmHg). |
From baseline (week 0) to week 32
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
CagriSema versus Semaglutide and Cagrilintide : Change in in-office systolic blood pressure
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in mmHg. |
From baseline (week 0) to week 32
|
|
Change in Home blood pressure monitoring (HBPM) -based systolic blood pressure
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in mmHg. |
From baseline (week 0) to week 32
|
|
Number of participants who achieve a target goal of in-office systolic blood pressure lesser than or equal to (≤) 130 mmHg
Periodo de tiempo: At Week 32
|
Measured as Count of participants. |
At Week 32
|
|
Number of participants who achieve American College of Cardiology and the American Heart Association (ACC/AHA) guidelines based blood pressure targets lesser than (<) 130/80 mmHg
Periodo de tiempo: At Week 32
|
Measured as Count of participants. |
At Week 32
|
|
Change in body weight (%)
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in percentage (%). |
From baseline (week 0) to week 32
|
|
Change in body weight (Kg)
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Kilograms (kg). |
From baseline (week 0) to week 32
|
|
Change in waist circumference
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in centimetre (cm). |
From baseline (week 0) to week 32
|
|
Change in ACC/AHA 10-year atherosclerotic cardiovascular disease (ASCVD) risk score
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in percentage of risk. ACC/AHA risk estimator calculates 10 year risk of ASCVD using a formula which includes age, sex, race, total cholesterol, high density lipoprotein (HDL) cholesterol, systolic blood pressure, blood pressure medication use, diabetes status, smoking status; minimum score 0, maximum score 100 where higher score indicates higher risk of 10-year risk of ASCVD. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: Total cholesterol
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: HDL cholesterol
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: Low Density Lipoprotein (LDL) cholesterol
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: Very Low Density Lipoprotein (VLDL) cholesterol
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: Non-HDL cholesterol
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of lipids: Triglycerides
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
|
Ratio to baseline of high-sensitivity C-reactive protein (hsCRP)
Periodo de tiempo: From baseline (week 0) to week 32
|
Measured in Ratio. |
From baseline (week 0) to week 32
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
Otros números de identificación del estudio
- NN9838-8768
- U1111-1338-1943 (Otro identificador: World Health Organization (WHO))
- 2026-526360-21 (Otro identificador: European Medical Agency (EMA))
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .